Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OrthoFill is a resorbable bone void filler developed by Kensey Nash Corporation (now part of DSM) and distributed by Biomet Sports Medicine (now Zimmer Biomet). It is a composite biomaterial engineered using Kensey Nash's proprietary Porous Tissue Matrix Technology, which creates foamed scaffolds for tissue engineering applications. The product is composed of a proprietary collagen formulation, a synthetic polymer, and a ceramic component, creating an osteoconductive structure optimized for bone regeneration. OrthoFill is designed to be packed into bony voids or gaps in the skeletal system, such as those in the extremities and pelvis, that are not intrinsic to the stability of the bone. It acts as a scaffold that facilitates the infiltration of bone-forming cells and is gradually resorbed and replaced by natural bone during the healing process. It received FDA 510(k) clearance in 2006.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OrthoFill.